潛伏結核感染治療為根除結核病的重要策略。本研究為比較潛伏結核感染治療中，3個月Isoniazid與Rifapentine短程治療處方（簡稱3HP）及9個月Isoniazid治療處方（簡稱9H）之完治率，並探討行動線索：都治關懷，以及行動障礙：副作用發生情形對於完治率之影響。本研究採用衛生福利部傳染病監測系統疫情資料倉儲（BO）之結核病接觸者管理資料，經選取臺北市2016年1月至2017年9月之潛伏結核感染個案之治療紀錄進行分析。
研究分析之個案共373人，97.9%加入都治方案，完治率達89.8%。其中317人接受3HP治療者，6.9%有發生副作用，89.3%完成治療；另56人接受9H治療處方者，僅1.8%發生副作用，92.8%完成治療，9H治療組之完治率高於3HP組，但沒有顯著不同。治療期間無發生副作用者的完治率，顯著高於有發生副作用者。9H治療組中，遠端都治個案的完治率95%，高於傳統都治個案之完治率89.3%，但無顯著差異。年齡為完成治療的預測因子，每增加1歲其完治的機率減少5%。建議持續推廣3HP短程的治療處方合併都治關懷治療潛伏結核感染者，並將遠端都治納入3HP都治關懷的服務選項，以強化高風險族群接受預防性治療的意願，使有效降低結核病發生之風險。

Treatment of latent tuberculosis infection (LTBI) is an important strategy toward TB elimination. The study was to evaluate the completion rate of 3 months of isoniazide and rifapentine regimen (3HP) and compared to 9 months of isoniazid regimen (9H). A retrospective data base study was employed to analyze the treatment of LTBI data from 2016 Jan to 2017 Sep in Taipei city from Business Objects (BO) system of Taiwan Centers for Disease Control (Taiwan CDC). Using Cox proportional hazards regression to examine the correlation of cues to action, DOPT, barriers of action, and side effect to the completion rate for latent tuberculosis infection treatment.
The total sample cases included in this study was 374, while 97.9% of the cases joined DOPT and had a completion rate of 89.8%. The 3HP regimens included 317 cases. 6.9% of them had side effects and the completion rate was 89.3%. The 9HP regimens had 56 cases. 1.8% of them had side effects and the completion rate was 92.8%. The completion rate for cases without side effects were significantly higher than those with side effects. Cases in 9HP regimens using telecare DOPT had 95% of completion rate while the regular DOPT hold a 89.3% completion rate. Age is the major predictor of completion rate. Completion rate decreases 5% for every one year increase of age. The 3HP regimens for DOPT with telecare is recomanded to elevate the acceptence of preventive treatment for LTBI.

一、中文文獻
李品慧、王貴鳳、詹珮君（2012）。2007年~2011年台灣結核病群聚事件分析。疫情報導，28（17），279-84。
李政益、王若珊、劉定萍、楊祥麟、黃湘芸（2014）。臺灣結核病流行概況與未來衝擊。疫情報導，30（6），105-117。
邱珠敏、杜純如、吳俊賢、黃士澤、王寰峯（2015）。台北區某校園結核病群聚感染事件調查處理經驗與省思。疫情報導，31（20），279-84。
周志浩主編（2017）。台灣結核病防治年報。臺北市：衛生福利部疾病管制署。
陳慕容（2010）。肺結核病患對結核病防治行為及其相關因素研究—以台北市某醫院為例。國立臺灣師範大學健康促進與衛生教育究所碩士論文，（未出版）。
黃伊文（2016）。以治療完成率及經濟效益來看短期12週療法對台灣潛伏結核感染之影響。中山醫學大學博士論文，（未出版）。
黃淑華、許建邦、王貴鳳、楊祥麟、黃彥芳、陳昶勳（2014）。我國結核病都治策略演進及執行監測機制。疫情報導，30（5），92-100。
詹珮君、蔡雅芬、馮琦芳、李品慧、王貴鳳、楊靖慧（2013）。臺灣結核病潛伏感染治療現況與未來。疫情報導，29（5）51 – 59。
臺北市政府衛生局（2017）。遠端視訊都治宣導短片。取自http://health.gov.taipei/Default.aspx?tabid=813
潘宗承、張瓊文、蔡韶慧、林宛蓁、鄭綉錦、賴珮芳、林明誠、柯靜芬、卓一嫻、朱嘉曦、魏嵩璽（2016）。潛伏結核感染治療成本分析，以中臺灣兩縣市為例。疫情報導，32（6），125-133。
衛生福利部（2015）。我國加入WHO 2035消除結核第一期計畫。取自http://www.cdc.gov.tw/professional/list.aspx?treeid=89b930c89c1c71cf&nowtreeid=48549c36029ae7b6
衛生福利部疾病管制署（2017a）。結核病診治指引。取自http://www.cdc.gov.tw/professional/info.aspx?treeid=89b930c89c1c71cf&nowtreeid=6744C19C09435458&tid=B02B73C3D6F15437
衛生福利部疾病管制署（2017b）。結核病防治工作手冊。取自https://www.cdc.gov.tw/professional/list.aspx?treeid=beac9c103df952c4&nowtreeid=37e21e0a5dcdb27c
衛生福利部疾病管制署（2017c）。潛伏結核全都治。取自 http://www.cdc.gov.tw/professional/info.aspx?treeid=BEAC9C103DF952C4&nowtreeid=F1D017CE6DFFBF55&tid=1DCECA3C62171B35

二、英文文獻
Anke, L. S., Marije, V. N-S., Femke, V. K., Anouk, M. O-S., Andreas, S., &Marieke, J. V. W. (2016). Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infectious Diseases ,16: 257.
Aliya, Y., Ethan, B., Rachel, H., Omar, M., & Russell, R. K. (2016).Predictors of Latent Tuberculosis Infection Treatment After Introduction of a New Regimen: A Retrospective Cohort Study at an Inner City Clinic. Open Forum Infectious Diseases. 3(4).
Bliven-Sizemore, E. E., Sterling, T. R., Shang, N., Benator, D., Schwartzman, K., Reves, R., Drobeniuc, J., Bock, N.& Villarino, M.E. (2015). Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. The International Journal of Tuberculosis and Lung Disease, 19(9), 1039-1044.
Becker, M. H. (1974). The Health Belief Model and Personal Health Behavior. Health Education Monography, 4,1-8.
Chang, A. H., Polesky, A., Bhatia, G. (2013). House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study. BMC Public Health, 13, 894.
Christopher, P., Brian, H., Fatemeh, Y., Dianna, W.,Candyce, H., Pauline, Q., Becky, S., David M., & Gonzalo, G. A. (2017). Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. Infectious Diseases, 17:265.
Comstock, G. W., Livesay, V. T.& Woolpert, S. F. (1974), The prognosis of a positive tuberculin reaction in childhood and adolescence. American Journal of Epidemiology, 99(2), 131-138.
Fincham, J. E.& Wertheimer, A. I. (1985).Using the health belief model to predict initial drug therapy defaulting. Social Science & Medicine, 20(1), 101-105.
Fox, G. J., Dobler, C. C., Marais, B. J.& Denholm, J.T. (2017). Review: Preventive therapy for latent tuberculosis infection—the promise and the challenges. International Journal of Infectious Diseases, 56.68-76.
Gilroy, S. A., Rogers, M. A.& Blair, D. C. (2000). Treatment of latent tuberculosis infection in patients aged > or =35 years. Clinical Infectious Diseases, 31(3), 826-829.
Holland, D. P., Sanders, G. D., Hamilton, C. D.& Stout, J. E. (2011) Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One, 6(7).
James, D. M., Lawrence, S., Peggy, C., Alan, T. (2001). The Application of Telemedicine Technology to a Directly Observed Therapy Program for Tuberculosis:A Pilot Project. Clinical Infectious Diseases, 33(12), 2082-4.
Li, J., Munsiff, S. S., Tarantino, T.& Dorsinville, M. (2010). Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. International Journal of Infectious Diseases, 4(4), e292-e297.
Maria, J. R., Mark, G., Alexander, C., Linda, K. & Neha, S. S. (2016) Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail. Open Forum Infectious Diseases, 3(1). ofv220.
Martinson, N. A., Barnes, G. L., Moulton, L. H., Msandiwa, R., Hausler, H. (2011). New regimens to prevent tuberculosis in adults with HIV infection. The New England Journal of Medicine, 365, 11–20.
Sharma, S. K., Sharma, A., Kadhiravan, T.& Tharyan, P. (2014). Rifamycins (rifampicin,rifabutinandrifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evidence-Based Child Health, 9, 169–294.
Sterling, T. R., Villarino, M. E., Borisov, A. S., Shang, N.& Gordin, F. (2011). Three months of rifapentine and isoniazid for latent tuberculosis infection. The New England Journal of Medicine, 365, 2155–2166.
Sterling, T. R., Moro, R. N., Borisov, A. S., Phillips, E., Shepherd, G., Adkinson, N. F., Weis, S., Ho, C.& Villarino, M.E. (2015). Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the prevent tuberculosis study. Clinical Infectious Diseases, 61(4),527-35.
World Health Organization. (2002). A Guideline for TB Treatment Supporters. Retrieved from http://whqlibdoc.who.int/hq/2002/WHO_CDS_TB_2002.300.pdf
World Health Organization. (2005).WHO Outbreak communication guidelines. Retrieved from www.who.int/csr/resources/publications/WHO_CDS_2005_28/en/
World Health Organization. (2014). The End TB Strategy Global Strategy and Targets forTuberculosis Prevention, Care and Control after 2015. Retrieved from http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1
World Health Organization. (2015). Guidelines on the management of latent tuberculosis infection. Retrieved from http://www. who.int/tb/publications/ltbi_document_page/en/
World Health Organization. (2017). Tuberculosis Fact Sheet. Retrieved from http://www.who.int/mediacentre/factsheets/fs104/en/